Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Neurogranin

Method of Measurement (Pre-analytical Tools)
CSF
Biomarker Measured
Neuronal damage
Use
Diagnostic
Susceptibility/risk
Stage of Development
Clinical trials
Active vs Completed Trials
Completed
Aim/Results

In recent years, studies have found the synaptic protein neurogranin to be consistently higher in people with Alzheimer’s disease compared with controls (effect size = 1.937, p <0.0001). Furthermore, baseline levels of the synaptic protein neurogranin were significantly higher in people with mild cognitive impairment who went on to develop Alzheimer’s dementia than in those who did not decline at follow-up (effect size = 1.542, p = 0.00299). These results were not consistent in plasma levels of neurograin (Levels of neurogranin in the plasma did not differ between people with Alzheimer’s disease and controls (effect size = 0.714, p = 0.25272)).

What is Required from Patients

Invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage

What is Required from the Health System

physican who can preform a lumbar puncture as well as a clinic designed for this testing, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

Data collected by multiple groups. Alzforum meta analysis.

  1. “Alzheimer's Disease vs Control: neurogranin (CSF).” Alzbiomarker. https://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-neurogranin-csf

  2. “Alzheimer's Disease vs Control: neurogranin (Plasma).” Alzbiomarker. https://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-neurogranin-plasma

  3. “MCI-AD vs MCI-Stable: neurogranin (CSF).” Alzbiomarker. https://www.alzforum.org/alzbiomarker/meta-analysis/mci-ad-vs-mci-stable-neurogranin-csf